ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bortezomib

Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.

Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.

Drug pageBortezomib: every studyMany companies study it; this page follows only the 62 they lead. All 651 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 15, 201462 company-led studies, 7 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only285 open or runningphase 4since Oct 15, 2014Sep 13, 2005Feb 14, 2029phase 3 · NCT04923893
Takedaits history only250 open or runningphase 4since Nov 18, 2005Oct 28, 2002none ahead
Oncotherapeuticsits history only40 open or runningphase 2since Apr 24, 2006Apr 19, 2006none ahead
AbbVie32 open or runningphase 3since Nov 28, 2023Aug 19, 2016Dec 2027phase 3 · NCT06158841
AstraZenecaits history only10 open or runningphase 4since Aug 23, 2023Aug 23, 2023none ahead
Clinical Service, Chinaits history only10 open or runningphase 2since Mar 29, 2011Mar 29, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2016First study: phase 2 study in Multiple MyelomaFirst studyNCT02902965 · 74 enrolled · Czechia, Germany, Greece and more
  2. Oct 11, 2017Phase 2 study in Multiple MyelomaNCT03314181 · 156 enrolled · United States, Australia, Canada and more
  3. Nov 28, 2023Phase 3 study in Multiple MyelomaNCT06158841 · 421 enrolled · United States, Australia, Austria and more

Ahead

  1. Dec 2027Primary completion: phase 3 study in Multiple MyelomaNCT06158841
  2. May 2031Primary completion: phase 2 study in Multiple MyelomaNCT03314181

TargetBeta

“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule

Other programs on the same 38 targets

ProgramCompanyFurthest phaseStudies
carfilzomibruleAmgenphase 438

Studies

All 3 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06158841Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingDec 2027421
NCT03314181Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingMay 2031156
NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more2CompletedOct 26, 201874

How it is read

Names in the registry

  • “Bortezomib”, 42 entries
  • “bortezomib”, 18 entries
  • “VELCADE”, 6 entries
  • “VELCADE TM (bortezomib) for Injection”, 2 entries
  • “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.